ClinicalTrials.gg
RecruitingNCT04218409Updated Nov 20, 2026

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

An Early Phase 1 interventional study of OxyCODONE 5 mg Oral Tablet and Oxytocin nasal spray in Pain, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Florida · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Planned enrollment
28th of 50
45 · median 67
Started
2021
with 1 other
Phase 1
10 of 50
2 open now
Registered
42nd of 50
by date
Lead sponsor
2 of 50
University of Florida

Among the 50 studies testing oxycodone in Pain, this one is the 28th largest by planned enrollment, is one of 2 that started in 2021, is one of 10 in phase 1, and was the 42nd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 21 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Read the detailed description

The overall project goals are to determine oxytocin effects on oxycodone's subject-rated abuse liability, experimental pain, and to describe the neurobehavioral mechanisms underlying interindividual differences in these effects. Generally healthy individuals (determined via medical history review and a screening session) will, after informed consent, self-administer intranasal oxytocin (or placebo, containing the same ingredients but no oxytocin) shortly after oral oxycodone or placebo in a non-residential, double-blind, randomized, placebo-controlled, within-subjects laboratory study. Prescreening will assure MRI eligibility and drug application safety and, using a validated, comprehensive pain history interview, determine previous or existing chronic pain conditions, including current pain medication use.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals fluent in English will participate.
  • Must report recreational use of opioids.
  • Be within 20% of their ideal body weight.
  • Are not currently experiencing chronic pain (pain on most days during the past 3 months)
  • Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
  • Participants must also have a normal (EKG) reading and bloodwork indicating no major health .

Exclusion criteria

Exclusion criteria:

  • Significant current physical disease or major psychiatric disorder.
  • No self-reported current interest in drug abuse treatment.
  • Women who are pregnant or nursing.
  • Any comorbid illicit substance use disorders or current withdrawal for any abused drug excluding nicotine and caffeine.
  • Any conditions that preclude safety in the MRI scanner, such as: implanted electrical devices (e.g., cardiac pacemaker, neurostimulator); implanted metallic clips or pins (e.g., aneurysm clip); a history of working with metal (unless able to demonstrate participant is MRI safe), and claustrophobia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    oxycodone (5mg) + intranasal oxytocin (48 IU)

    Combined effects of oxycodone and oxytocin

    Drug: OxyCODONE 5 mg Oral Tablet · Drug: Oxytocin nasal spray

  • Active comparator
    Oral oxycodone (5mg) + intranasal placebo

    Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo

    Drug: OxyCODONE 5 mg Oral Tablet · Other: Placebo oxytocin

  • Active comparator
    oxytocin+placebo

    Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo

    Drug: Oxytocin nasal spray · Other: Placebo Oxycodone

  • Sham comparator
    placebo+placebo

    Serves as the control

    Other: Placebo Oxycodone · Other: Placebo oxytocin

  • Active comparator
    Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)

    Combined effects of oxycodone and oxytocin

    Drug: Oxytocin nasal spray · Drug: OxyCODONE 2.5 mg Oral Tablet

  • Active comparator
    Oral oxycodone (2.5mg) + intranasal placebo

    Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo

    Other: Placebo oxytocin · Drug: OxyCODONE 2.5 mg Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Subject-rated abuse liability

    Using a Visual Analog Scale with scoring as 0=not at all, 20=possibly mild, 40=definitely mild, 60=moderately, 80=strongly, and 100=extremely, or any number in between. Testing occurs only in the context of 4 sessions due to a minimum of a one week washout period in between each session.

    Time frame: up to 6 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Mar 2028, 78 months after the start.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 78 months is above that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2026 → Mar 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2020
First posted
Jan 6, 2020
StartActual
Sep 2, 2021
Primary completionEst.
Mar 2028was Dec 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Mar 2028
Nov 20, 2026
Study completion
Dec 31, 2026→Dec 2028
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Dec 31, 2026→Mar 2028
    Study completion Dec 31, 2026→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04218409
Responsible party
Sponsor
First posted
Jan 6, 2020
Start date
Sep 2, 2021
Primary completion
Mar 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Lauren Nieder
Contact
lauren.nieder@ufl.edu
352-294-1067
Meredith Berry, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Oxytocin

Start the discussion